We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling ResMed (RMD) Q1 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that ResMed (RMD - Free Report) will announce quarterly earnings of $2.03 per share in its forthcoming report, representing an increase of 23.8% year over year. Revenues are projected to reach $1.19 billion, increasing 7.9% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.5% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific ResMed metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Global revenue- Devices' to reach $594.99 million. The estimate indicates a year-over-year change of +5.4%.
The consensus among analysts is that 'Global revenue- Software as a Service' will reach $163.09 million. The estimate indicates a year-over-year change of +17.1%.
Analysts' assessment points toward 'Global revenue- Total Sleep and Respiratory Care' reaching $1.02 billion. The estimate points to a change of +6.1% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Global revenue- Masks' of $426.53 million. The estimate indicates a year-over-year change of +7.1%.
Analysts expect 'U.S., Canada, and Latin America- Devices' to come in at $366.97 million. The estimate points to a change of +6.1% from the year-ago quarter.
Analysts predict that the 'U.S., Canada, and Latin America- Masks' will reach $311.67 million. The estimate indicates a change of +6.6% from the prior-year quarter.
It is projected by analysts that the 'Combined Europe, Asia, and other markets- Total Sleep and Respiratory Care' will reach $342.88 million. The estimate suggests a change of +5.6% year over year.
According to the collective judgment of analysts, 'Combined Europe, Asia, and other markets- Devices' should come in at $228.02 million. The estimate points to a change of +4.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Combined Europe, Asia, and other markets- Masks' should arrive at $114.86 million. The estimate indicates a change of +8.6% from the prior-year quarter.
The consensus estimate for 'U.S., Canada, and Latin America- Total' stands at $678.63 million. The estimate points to a change of +6.3% from the year-ago quarter.
Over the past month, ResMed shares have recorded returns of -2% versus the Zacks S&P 500 composite's +4.5% change. Based on its Zacks Rank #2 (Buy), RMD will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unveiling ResMed (RMD) Q1 Outlook: Wall Street Estimates for Key Metrics
Analysts on Wall Street project that ResMed (RMD - Free Report) will announce quarterly earnings of $2.03 per share in its forthcoming report, representing an increase of 23.8% year over year. Revenues are projected to reach $1.19 billion, increasing 7.9% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.5% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Bearing this in mind, let's now explore the average estimates of specific ResMed metrics that are commonly monitored and projected by Wall Street analysts.
Analysts forecast 'Global revenue- Devices' to reach $594.99 million. The estimate indicates a year-over-year change of +5.4%.
The consensus among analysts is that 'Global revenue- Software as a Service' will reach $163.09 million. The estimate indicates a year-over-year change of +17.1%.
Analysts' assessment points toward 'Global revenue- Total Sleep and Respiratory Care' reaching $1.02 billion. The estimate points to a change of +6.1% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Global revenue- Masks' of $426.53 million. The estimate indicates a year-over-year change of +7.1%.
Analysts expect 'U.S., Canada, and Latin America- Devices' to come in at $366.97 million. The estimate points to a change of +6.1% from the year-ago quarter.
Analysts predict that the 'U.S., Canada, and Latin America- Masks' will reach $311.67 million. The estimate indicates a change of +6.6% from the prior-year quarter.
It is projected by analysts that the 'Combined Europe, Asia, and other markets- Total Sleep and Respiratory Care' will reach $342.88 million. The estimate suggests a change of +5.6% year over year.
According to the collective judgment of analysts, 'Combined Europe, Asia, and other markets- Devices' should come in at $228.02 million. The estimate points to a change of +4.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Combined Europe, Asia, and other markets- Masks' should arrive at $114.86 million. The estimate indicates a change of +8.6% from the prior-year quarter.
The consensus estimate for 'U.S., Canada, and Latin America- Total' stands at $678.63 million. The estimate points to a change of +6.3% from the year-ago quarter.
View all Key Company Metrics for ResMed here>>>
Over the past month, ResMed shares have recorded returns of -2% versus the Zacks S&P 500 composite's +4.5% change. Based on its Zacks Rank #2 (Buy), RMD will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>